Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Bayer |
---|---|
Information provided by: | Bayer |
ClinicalTrials.gov Identifier: | NCT00651469 |
The objectives of this study were to evaluate the efficacy and safety of drospirenone 3 mg/ethinyl estradiol 0.02 mg (DRSP/EE) in comparison with placebo in female subjects with moderate acne vulgaris during 6 treatment cycles.
Condition | Intervention | Phase |
---|---|---|
Acne Vulgaris |
Drug: YAZ (DRSP 3 mg/EE 0.02 mg (as Beta-Cyclodextrin Clathrate)) Drug: Placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety & Efficacy of Oral Contraceptive Prep., Containing Drospirenone 3 mg/Ethinyl Estradiol 20 Mcg for 6 Treatment Cycles in Women With Moderate Acne Vulgaris. |
Enrollment: | 500 |
Study Start Date: | January 2003 |
Study Completion Date: | July 2004 |
Arms | Assigned Interventions |
---|---|
Arm 1: Experimental
n/a
|
Drug: YAZ (DRSP 3 mg/EE 0.02 mg (as Beta-Cyclodextrin Clathrate))
The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack. Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle). |
Arm 2: Placebo Comparator
n/a
|
Drug: Placebo
The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
|
Ages Eligible for Study: | 14 Years to 45 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Female age 14-45, with 10 to 100 comedones (noninflammatory lesions), 10 to 50 inflammatory lesions (papules or pustules), and not more than 35 nodules (<5mm) on the face).
Exclusion Criteria:
Study Director: | Bayer Study Director | Bayer |
Responsible Party: | ( Bayer Schering Pharma AG, Therapeutic Area Head ) |
Study ID Numbers: | 91209, 306820 |
Study First Received: | March 31, 2008 |
Last Updated: | May 26, 2008 |
ClinicalTrials.gov Identifier: | NCT00651469 |
Health Authority: | United States: Food and Drug Administration |
Moderate Acne Vulgaris Acne |
Facial Dermatoses Skin Diseases Facies Estradiol valerate Ethinyl Estradiol Sebaceous Gland Diseases Estradiol 17 beta-cypionate |
Acne Vulgaris Estradiol Exanthema Estradiol 3-benzoate Drospirenone Polyestradiol phosphate |
Acneiform Eruptions |